(Washington, D.C.) — As the House Committee on Oversight and Reform continues its investigation into drug manufacturers’ pricing strategies, the Pharmaceutical Care Management Association (PCMA) is releasing new data on the impact of blocking competition for top-selling medications. Brand-name drug manufacturers
Unlocking an Affordable Future: Key #1 Ensure System Sustainability ENSURE SYSTEM SUSTAINABILITY BY PROMOTING COMPETITION A competitive private market is the best way to manage drug costs. Interventions should be focused on fixing specific market failures or gaps rather than
(Washington D.C.) – Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on today’s Senate Finance Committee hearing, “Prescription Drug Price Inflation: An Urgent Need to Lower Drug Prices in Medicare.” “PCMA commends the Senate Finance Committee
In case you missed it, Ike Brannon, senior fellow at the Jack Kemp Foundation and former senior economist for the United States Treasury and U.S. Congress, explains the problem with misguided policies targeting pharmacy benefit companies in a new RealClearMarkets
PBM Tools PBM Tools Will Save Health Plan Sponsors and Consumers More than $1 Trillion on Prescription Drug Costs As prescription drug spending continues to increase, research shows PBMs’ cost savings and patient care management tools should reduce prescription drug
High Priced Drugs America’s PBMs are the only member of the prescription drug supply and payment chain working to reduce high drug costs, improve patient access, and increase affordability. PBMs administer prescription drug plans for more than 266 million Americans
Proponents of policies targeting pharmacy benefit companies ignore the costly repercussions of undermining pharmacy benefit managers’ (PBMs) ability to secure savings that enable health plan sponsors to offer quality, affordable prescription drug benefits. Proposals being pushed to “lower drug costs” that
With so many important issues being debated today, there are few topics that health care, legal, and economic experts agree on. But the fact that drug companies are the root cause of high prescription drug prices is one common denominator
©2024 PCMA. All Rights Reserved.
